[go: up one dir, main page]

UY26495A1 - " derivados de tiazolilamida" - Google Patents

" derivados de tiazolilamida"

Info

Publication number
UY26495A1
UY26495A1 UY26495A UY26495A UY26495A1 UY 26495 A1 UY26495 A1 UY 26495A1 UY 26495 A UY26495 A UY 26495A UY 26495 A UY26495 A UY 26495A UY 26495 A1 UY26495 A1 UY 26495A1
Authority
UY
Uruguay
Prior art keywords
thiazolylamide
derivatives
thiazolylamide derivatives
drugs
preparation
Prior art date
Application number
UY26495A
Other languages
English (en)
Inventor
Dr Rudiger Fischer
Dr Gerard Kleymann
Dr Ulrich Betz
Dr Judith Baumeister
Dr Wolfgang Bender
Dr Peter Eckenberg
Dr Gabriele Handke
Dr Martin Hendrix
Dr Kerstin Henninger
Dr Axel Jensen
Dr Jorg Keldenich
Dr Udo Schneider
Dr Olaf Weber
Dr Gerald Kleymann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19962532A external-priority patent/DE19962532A1/de
Priority claimed from DE10039265A external-priority patent/DE10039265A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY26495A1 publication Critical patent/UY26495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, a un procedimiento para su preparación así como a su uso como medicamentos, especialmente como medicamentos antivíricos.
UY26495A 1999-12-23 2000-12-20 " derivados de tiazolilamida" UY26495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19962532A DE19962532A1 (de) 1999-12-23 1999-12-23 Thiazolylamid-Derivate
DE10039265A DE10039265A1 (de) 2000-08-11 2000-08-11 Thiazolylamid-Derivate

Publications (1)

Publication Number Publication Date
UY26495A1 true UY26495A1 (es) 2001-07-31

Family

ID=26006669

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26495A UY26495A1 (es) 1999-12-23 2000-12-20 " derivados de tiazolilamida"

Country Status (26)

Country Link
US (1) US7105553B2 (es)
EP (1) EP1244641B1 (es)
JP (1) JP4726175B2 (es)
KR (1) KR100768361B1 (es)
CN (1) CN1235890C (es)
AR (1) AR029210A1 (es)
AT (1) ATE293104T1 (es)
AU (1) AU784286B2 (es)
BR (1) BR0017030B8 (es)
CA (1) CA2396720C (es)
CO (1) CO5261491A1 (es)
DE (1) DE50010060D1 (es)
DK (1) DK1244641T3 (es)
DO (1) DOP2000000109A (es)
ES (1) ES2240233T3 (es)
IL (2) IL149897A0 (es)
MX (1) MXPA02006243A (es)
MY (1) MY134880A (es)
NZ (1) NZ519701A (es)
PE (1) PE20010964A1 (es)
PL (1) PL208707B1 (es)
PT (1) PT1244641E (es)
SV (1) SV2002000249A (es)
TW (1) TWI256951B (es)
UY (1) UY26495A1 (es)
WO (1) WO2001047904A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000259734A1 (en) * 2000-06-15 2001-12-24 Gerald Kleymann Method for identifying compounds with anti-herpes activity
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
DK2578229T3 (da) * 2004-09-09 2013-10-07 Novartis Vaccines & Diagnostic Faldende potentielle iatrogene risici associeret med vaccine-antigener
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
MX2007015216A (es) * 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
AU2006295260A1 (en) * 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
SI2586434T1 (sl) * 2006-03-17 2016-09-30 The Johns Hopkins University Derivati n-hidroksilsulfonamida kot novi fiziološko uporabni donorji nitroksila
WO2008140583A2 (en) * 2006-11-22 2008-11-20 The Regents Of The University Of California Functionalized boron nitride nanotubes
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
AU2014217962A1 (en) * 2013-02-12 2015-09-17 Aicuris Gmbh & Co. Kg Helicase-primase inhibitors for use in a method of treating Alzheimer's Disease
CA2954526C (en) * 2014-07-07 2023-03-07 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
MX375099B (es) * 2016-04-06 2025-03-06 Innovative Molecules Gmbh Derivados de aminotiazol útiles como agentes antivíricos.
ES2941390T3 (es) * 2016-11-28 2023-05-22 Aicuris Gmbh & Co Kg Hemihidrato de la base libre de la N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida, métodos de fabricación y sus usos
CN117186084A (zh) 2016-11-28 2023-12-08 艾库里斯有限及两合公司 普瑞利韦磺酸盐、其药物制剂、制造方法及治疗疱疹病毒的用途
AR110250A1 (es) 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
JP7150343B2 (ja) * 2017-01-09 2022-10-11 フェーノ・セラピューティクス・カンパニー・リミテッド チアゾール誘導体およびその使用
WO2019068817A1 (en) * 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
CN112384512B (zh) * 2018-07-06 2022-03-29 辉诺生物医药科技（杭州）有限公司 噻唑类化合物的晶型及其应用
EP3925595A1 (en) 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4096632A1 (en) 2020-03-26 2022-12-07 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
CN116783171A (zh) * 2020-10-29 2023-09-19 创新分子股份有限公司 作为抗病毒化合物的氘化氨基噻唑化合物
CA3246779A1 (en) 2022-01-17 2023-07-20 Innovative Molecules Gmbh SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD
CA3255969A1 (en) 2022-05-20 2023-11-23 Gilead Sciences, Inc. Indolinyl Antiviral Compounds and Their Uses
CN119816497A (zh) 2022-08-29 2025-04-11 组装生物科学股份有限公司 普瑞利韦的新的结晶形式
EP4581031A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
IL319024A (en) 2022-08-29 2025-04-01 Assembly Biosciences Inc Pharmaceutical preparations for the herpes virus
CR20250099A (es) 2022-08-29 2025-07-29 Assembly Biosciences Inc Compuestos cíclicos de urea tiazolilo para el tratamiento del hsv
AU2024263350A1 (en) 2023-04-26 2025-11-06 Assembly Biosciences, Inc. Oral pharmaceutical compositions
WO2025046456A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025046457A1 (en) 2023-08-28 2025-03-06 Assembly Biosciences, Inc. A crystalline form of 2-(3-(2,,5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydropyrimidin-1(2h)-yl)-4-methylthiazole-5-sulfonamide
WO2025111598A1 (en) 2023-11-22 2025-05-30 Assembly Biosciences, Inc. Azetidine compounds for treatment of hsv
WO2025172927A1 (en) 2024-02-16 2025-08-21 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2026015761A1 (en) 2024-07-12 2026-01-15 Assembly Biosciences, Inc. Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658830A (en) 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
NL7100497A (es) 1970-01-16 1971-07-20
US3847588A (en) 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
US3717651A (en) 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
DE69624728T2 (de) 1995-12-29 2003-07-10 Boehringer Ingelheim (Canada) Ltd., Laval Phenyl thiazol derivate mit antiherpesvirus eigenschaften
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
ES2189404T3 (es) 1998-03-19 2003-07-01 Upjohn Co 1,3,4-tiadiazoles utiles para el tratamiento de infecciones por cmv.
CA2366607A1 (en) 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents

Also Published As

Publication number Publication date
EP1244641B1 (de) 2005-04-13
CN1434812A (zh) 2003-08-06
MY134880A (en) 2007-12-31
ATE293104T1 (de) 2005-04-15
BR0017030B1 (pt) 2013-10-01
MXPA02006243A (es) 2003-01-28
DK1244641T3 (da) 2005-07-11
SV2002000249A (es) 2002-06-07
IL149897A (en) 2008-08-07
PL208707B1 (pl) 2011-05-31
JP2003519134A (ja) 2003-06-17
CN1235890C (zh) 2006-01-11
AR029210A1 (es) 2003-06-18
EP1244641A1 (de) 2002-10-02
CA2396720A1 (en) 2001-07-05
KR20020067568A (ko) 2002-08-22
IL149897A0 (en) 2002-11-10
PE20010964A1 (es) 2001-11-10
US7105553B2 (en) 2006-09-12
PL356484A1 (en) 2004-06-28
DOP2000000109A (es) 2002-08-30
HK1057552A1 (en) 2004-04-08
PT1244641E (pt) 2005-08-31
ES2240233T3 (es) 2005-10-16
NZ519701A (en) 2004-05-28
DE50010060D1 (de) 2005-05-19
CO5261491A1 (es) 2003-03-31
TWI256951B (en) 2006-06-21
BR0017030A (pt) 2003-01-07
CA2396720C (en) 2009-09-22
US20040006076A1 (en) 2004-01-08
WO2001047904A1 (de) 2001-07-05
JP4726175B2 (ja) 2011-07-20
KR100768361B1 (ko) 2007-10-18
BR0017030B8 (pt) 2021-05-25
AU784286B2 (en) 2006-03-02
AU3157401A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
UY26495A1 (es) " derivados de tiazolilamida"
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
UY27098A1 (es) Derivados de indol
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
BRPI9914571B8 (pt) composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
CO5011066A1 (es) Compuestos de triazina
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
ECSP045271A (es) Derivados de quinolina
ID27733A (id) Metoksiminofenilasetamida
ECSP003843A (es) Derivados de tiazolilamida
UY26435A1 (es) Compuestos bis-básicos como inhibidores de triptasa, procedimiento para su preparación y su utilización como medicamentos.
AR025073A1 (es) Proceso para la preparacion de compuestos de 1,3-dicarbonilo acilados
BR0213329A (pt) Processo para preparação de 14beta-hidróxi-baccatin iii-1,14carbonato
ITMI20022534A1 (it) Procedimento per la preparazione di terbinafina mediante l'uso di platino come catalizzatore.
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
ECSP972189A (es) Nuevas triazolopurinas, procedimientos para su preparacion y su empleo como medicamentos
GT199900057A (es) Procedimiento para la preparaciòn de ( s , s ) - bencil - 2,8 - diazabiciclo 4.3.0. nonano.
ECSP982594A (es) Oxazolidinonas triciclicamente sustituidas
MXPA04001851A (es) Inda-1-onas c2-disustituidas y sus derivados, metodo para su produccion y su uso como medicamentos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161107